Soluble PD-1 variants, fusion constructs, and uses thereof

• US 9,029,315 B2
• Filed: 11/11/2011
• Issued: 05/12/2015
• Est. Priority Date: 11/11/2010
• Status: Active Grant

• Current Assignee: Versitech Limited (Government of Hong Kong Special Administrative Region)
• Original Assignee: University of Hong Kong (Government of Hong Kong Special Administrative Region)
• Inventors: Chen, Zhiwei, Zhou, Jingying
• Primary Examiner(s): Humphrey, Louise
• Assistant Examiner(s): SNYDER, STUART
• Application Number:
  US13/294,306
• Publication Number:
  US 20120121634A1
• Time in Patent Office: 1,278 Days
• Field of Search: None
• US Class Current: 514/1
• CPC Class Codes: A61K 2039/53 DNA (RNA) vaccination
• CPC Class Codes: A61K 2039/54 characterised by the route of administration
• CPC Class Codes: A61K 2039/57 characterised by the type of response, e.g. Th1, Th2
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 39/21 Retroviridae, e.g. equine infectious anemia virus
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: A61P 31/16 for influenza or rhinoviruses
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: A61P 31/22 for herpes viruses
• CPC Class Codes: A61P 33/00 Antiparasitic agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C07K 14/70521 CD28, CD152
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
• CPC Class Codes: C07K 2319/32 fusions with soluble part of a cell surface receptor, "decoy receptors"
• CPC Class Codes: C07K 2319/33 fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
• CPC Class Codes: C12N 2740/16034 : Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2740/16222 : New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

The subject invention provides novel soluble PD-1 (sPD-1) proteins, nucleic acids, and fusion constructs thereof, for enhancing humoral and cell-mediated immunity of a subject. Also provided are therapeutic compositions comprising the sPD-1 proteins, nucleic acids, and fusion constructs of the subject invention. In a preferred embodiment, the therapeutic composition is formulated as a vaccine composition. Advantageously, the sPD-1 proteins, nucleic acids, and therapeutic compositions provide protective immunity against pathogenic infection including HIV infection. In addition, the subject invention can be used in the prevention and/or treatment of tumor or cancer.

Claims

1. A PD-1 DNA molecule encoding a soluble PD-1 protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:

11, SEQ ID NO;

15, and SEQ ID NO;

25.

2. A sPD-1 fusion nucleic acid molecule encoding a PD-1 fusion protein, the fusion protein comprising a soluble PD-1 protein fragment and an antigenic protein fragment, wherein the soluble PD-1 protein fragment comprises an amino acid sequence selected from the group consisting of SEQ ID NO:

1, SEQ ID NO;

21, SEQ ID NO;

11, SEQ ID NO;

15, and SEQ ID NO;

25.

3. The sPD-1 fusion nucleic acid molecule of claim 2, wherein the nucleic acid molecule comprises a sequence of SEQ ID NO:

24.

4. A vaccine composition comprising the sPD-1 fusion nucleic acid molecule of claim 2.